SCHEMBL4515775

SCHEMBL4515775

N#CC1(c2ccc(-c3ccc(C(=O)c4ccccc4)cc3)c(F)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 6/20 0.46
CYP2C19 P33261 5/20 0.46
CYP3A4 P08684 5/20 0.46
CYP2C9 P11712 4/20 0.46
CYP2D6 P10635 2/20 0.46
HDAC1 Q13547 1/20 0.43
NPC1 O15118 2/20 0.43
ALDH1A1 P00352 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
AKR1C3 P42330 6/20 0.42
AKR1C2 P52895 6/20 0.42
AKR1C1 Q04828 3/20 0.42
FFAR4 Q5NUL3 3/20 0.42
AKR1B10 O60218 1/20 0.42
AKR1C4 P17516 1/20 0.42
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4507377 0.86 APP (0.47) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL4493375 0.86 APP (0.43) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL4514624 0.85 APP (0.45) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL4501054 0.83 APP (0.47) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL4506449 0.82 APP (0.43) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL4503491 0.80 AKR1C3 (0.46) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL4503288 0.79 OPRM1 (0.38) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL4504736 0.78 AKR1C3 (0.43) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL4491283 0.78 FFAR4 (0.45) APPCYP2C19CYP3A4CYP2C9CYP2D6
SCHEMBL4503949 0.78 OPRM1 (0.47) APPCYP2C19CYP3A4CYP2C9CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291988-A1 Reversible Inhibitors of Monoamine Oxidase A and B MERCK FROSST CANADA LTD. (CA) 2009-11-26 US claimed
EP-1893562-A1 REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B Merck Frosst Canada Ltd. (CA) 2008-03-05 EP claimed
WO-2006133559-A1 REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B MERCK FROSST CANADA LTD. (CA) 2006-12-21 WO claimed
US-20090291988-A1 Reversible Inhibitors of Monoamine Oxidase A and B MERCK FROSST CANADA LTD. (CA) 2009-11-26 US disclosed
EP-1893562-A1 REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B Merck Frosst Canada Ltd. (CA) 2008-03-05 EP disclosed
WO-2006133559-A1 REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B MERCK FROSST CANADA LTD. (CA) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291988-A1 Reversible Inhibitors of Monoamine Oxidase A and B MAOB, MAOA, XDH APP 1024/4885CYP2C19 66/4885CYP3A4 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.